Physician profile
Robert A Figlin
NPI 1780609966
$154,873.18
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,548 · 2020: $17K · 2021: $16K · 2022: $3,463 · 2023: $46K · 2024: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $110K · Travel and Lodging: $806 · Food and Beverage: $112 · Education: $25.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $110,466.22 |
| Travel and Lodging | $806.04 |
| Food and Beverage | $111.84 |
| Education | $25.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| 4dmedical USA INC | $108,485.58 | 2023-2024 | Ct Lvas |
| Exelixis INC. | $16,658.09 | 2019-2022 | |
| Eisai INC. | $13,518.83 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $5,203.07 | 2020 | |
| Merck Sharp & Dohme LLC | $5,000.00 | 2020-2022 | |
| Kyowa Kirin, INC. | $2,786.68 | 2024 | |
| Pfizer INC. | $1,538.94 | 2019-2024 | |
| Janssen Research & Development, LLC | $1,500.00 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $70.15 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $62.59 | 2023 | |
| Iovance Biotherapeutics, INC. | $49.25 | 2024 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Figlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.